LLY

1,011

-0.04%↓

JNJ

202.26

+0.1%↑

ABBV

226.05

-0.99%↓

UNH

329.2

-1.5%↓

AZN

90.22

+0.03%↑

LLY

1,011

-0.04%↓

JNJ

202.26

+0.1%↑

ABBV

226.05

-0.99%↓

UNH

329.2

-1.5%↓

AZN

90.22

+0.03%↑

LLY

1,011

-0.04%↓

JNJ

202.26

+0.1%↑

ABBV

226.05

-0.99%↓

UNH

329.2

-1.5%↓

AZN

90.22

+0.03%↑

LLY

1,011

-0.04%↓

JNJ

202.26

+0.1%↑

ABBV

226.05

-0.99%↓

UNH

329.2

-1.5%↓

AZN

90.22

+0.03%↑

LLY

1,011

-0.04%↓

JNJ

202.26

+0.1%↑

ABBV

226.05

-0.99%↓

UNH

329.2

-1.5%↓

AZN

90.22

+0.03%↑

Kodu・Aktsiate loetelu・Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc

Avatud

SektorTervishoid

44.95 1.51

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

43.92

Max

44.94

Põhinäitajad
By Trading Economics
Sissetulek	-6.2M -91M
Kasumimarginaal	-867.293
Töötajad	316
EBITDA	4M -90M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+25.51% upside

Turustatistika
By TradingEconomics
Turukapital	132M 3.4B
Eelmine avamishind	43.44
Eelmine sulgemishind	44.95

Uudiste sentiment

By Acuity

50%

178 / 374 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Strong Bearish Evidence

34.81 / 38.24 Toetus ja vastupanu

Xenon Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

4. dets 2025, 20:41 UTC

Tulu

Suurimad hinnamuutused turgudel

America's Car-Mart Rises on Better-Than-Expected 2Q Revenue, $300 Million Term Loan

4. dets 2025, 18:14 UTC

Omandamised, ülevõtmised, äriostud

Big Yellow Says It Will Terminate Takeover Talks With Blackstone

4. dets 2025, 17:43 UTC

Suurimad hinnamuutused turgudel

Omandamised, ülevõtmised, äriostud

Brera Holdings Signs Non-Binding Term Sheet to Acquire RockawayX

4. dets 2025, 17:01 UTC

Tulu

TD Bank Pushes Up Dividend After Underlying Earnings, Revenue Beat Expectations -- Update

4. dets 2025, 23:45 UTC

Market Talk

Nikkei May Decline Amid Caution Over U.S. Labor Market, Japan Earnings -- Market Talk

4. dets 2025, 23:45 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

4. dets 2025, 21:54 UTC

Market Talk

Global Equities Roundup: Market Talk

4. dets 2025, 21:54 UTC

Market Talk

Warehouse's Strategy to Lift Margins Easier Said Then Done -- Market Talk

4. dets 2025, 21:50 UTC

Market Talk

Financial Services Roundup: Market Talk

4. dets 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

4. dets 2025, 21:48 UTC

Market Talk

Scales Hits Mark With Earnings Guidance -- Market Talk

4. dets 2025, 21:37 UTC

Tulu

Aerospace Start-Up Beta Posts Its First Earnings Report. The Stock Rises. -- Barrons.com

4. dets 2025, 21:36 UTC

Tulu

These Stocks Moved the Most Today: Meta Platforms, Salesforce, Snowflake, UiPath, Micron, Dollar General, Kroger, and More -- Barrons.com

4. dets 2025, 20:15 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

4. dets 2025, 20:15 UTC

Market Talk

Think Tank Calls For Bank of Canada Rate Hold Next Week -- Market Talk

4. dets 2025, 20:04 UTC

Market Talk

Natural Gas Futures Extend Gains as U.S. Grows Cold -- Market Talk

4. dets 2025, 19:54 UTC

Market Talk

Oil Futures Bolstered by Lasting Ukraine War, U.S. Macro Outlook -- Market Talk

4. dets 2025, 19:44 UTC

Omandamised, ülevõtmised, äriostud

EQB CEO: PC Financial Deal Adds Scale to Compete With Larger Canadian Banks

4. dets 2025, 19:44 UTC

Omandamised, ülevõtmised, äriostud

EQB CEO: PC Financial Tie-Up Brings Scale to Reach More Customers

4. dets 2025, 19:44 UTC

Omandamised, ülevõtmised, äriostud

Equitable Bank Deal for PC Financial Adds Heft to Compete With Canada's Big Banks -- Interview

4. dets 2025, 19:33 UTC

Market Talk

Gold Inches Higher as Traders Continue to Mull ADP Jobs Report -- Market Talk

4. dets 2025, 19:01 UTC

Omandamised, ülevõtmised, äriostud

Paramount Raises Concerns About Netflix's Bid for Warner Bros. Discovery -- WSJ

4. dets 2025, 19:01 UTC

Omandamised, ülevõtmised, äriostud

Paramount Wrote to Warner Bros. Discovery Again Wednesday -- WSJ

4. dets 2025, 19:01 UTC

Omandamised, ülevõtmised, äriostud

Paramount Wrote Netflix Deal With Warner Bros. Would Likely 'Never Close,' Monday Letter Says -- WSJ

4. dets 2025, 19:01 UTC

Omandamised, ülevõtmised, äriostud

Another Round of Bids for Warner Bros. Discovery Due Thursday, Sources Say -- WSJ

4. dets 2025, 18:58 UTC

Market Talk

U.S.-Venezuela Military Tension Expected to Lift Oil Prices -- Market Talk

4. dets 2025, 17:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

4. dets 2025, 17:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

4. dets 2025, 16:41 UTC

Market Talk

Gold Rises as Traders Await U.S. Inflation Data -- Market Talk

4. dets 2025, 16:33 UTC

Market Talk

Tulu

Salesforce Customers Are Gaining Confidence in Agentforce -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Xenon Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

25.51% tõus

12 kuu keskmine prognoos

Keskmine 55.59 USD 25.51%

Kõrge 65 USD

Madal 44 USD

Põhineb 14 Wall Streeti analüütiku instrumendi Xenon Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

14 ratings

Osta

Hoia

Müü

Põhineb 14 analüütiku instrumendi Xenon Pharmaceuticals Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

34.81 / 38.24Toetus ja vastupanu

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

178 / 374 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.